Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study
Male
2. Zero hunger
Cancer och onkologi
Prostate cancer
Smoking
Klinisk medicin
Prostatic Neoplasms
Prostate-Specific Antigen
3. Good health
03 medical and health sciences
0302 clinical medicine
Risk Factors
Cancer and Oncology
Urologi och njurmedicin
Urology and Nephrology
Humans
Prospective Studies
Obesity
Prospective study
Clinical Medicine
DOI:
10.1016/j.eururo.2022.03.033
Publication Date:
2022-05-04T10:57:27Z
AUTHORS (6)
ABSTRACT
Prospective and detailed investigations of smoking and prostate cancer (PCa) risk and death are lacking.To investigate prediagnosis smoking habit (status, intensity, duration, and cessation) as a risk factor, on its own and combined with body mass index (BMI), for PCa incidence and death.We included 351448 men with smoking information from five Swedish cohorts.We used Cox regression to calculate hazard ratios (HRs) and confidence intervals (CIs) for PCa incidence (n = 24731) and death (n = 4322).Smoking was associated with a lower risk of any PCa (HR 0.89, 95% CI 0.86-0.92), which was most pronounced for low-risk PCa (HR 0.74, 95% CI 0.69-0.79) and was restricted to PCa cases diagnosed in the prostate-specific antigen (PSA) era. Smoking was associated with a higher risk of PCa death in the full cohort (HR 1.10, 95% CI 1.02-1.18) and in case-only analysis adjusted for clinical characteristics (HR 1.20, 95% CI 1.11-1.31), which was a consistent finding across case groups (p = 0.8 for heterogeneity). Associations by smoking intensity and, to lesser degree, smoking duration and cessation, supported the associations for smoking status. Smoking in combination with obesity (BMI ≥30 kg/m2) further decreased the risk of low-risk PCa incidence (HR 0.40, 95% CI 0.30-0.53 compared to never smokers with BMI <25 kg/m2) and further increased the risk of PCa death (HR 1.49, 95% CI 1.21-1.84). A limitation of the study is that only a subgroup of men had information on smoking habit around the time of their PCa diagnosis.The lower PCa risk for smokers in the PSA era, particularly for low-risk PCa, can probably be attributed to low uptake of PSA testing by smokers. Poor survival for smokers, particularly obese smokers, requires further study to clarify the underlying causes and the preventive potential of smoking intervention for PCa death.Smokers have a higher risk of dying from prostate cancer, which further increases with obesity.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (47)
CITATIONS (26)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....